德纳姆
生物年龄
生物学价值
安慰剂
医学
老年学
DNA甲基化
生物
生物信息学
遗传学
病理
基因
基因表达
替代医学
作者
O. V. Demidenko,Diogo Barardo,Valery Budovskii,Robb Finnemore,Francis R Palmer,Brian K. Kennedy,Yelena V. Budovskaya
出处
期刊:Aging
[Impact Journals, LLC]
日期:2021-11-30
卷期号:13 (22): 24485-24499
被引量:17
标识
DOI:10.18632/aging.203736
摘要
The search continues for possible interventions that delay and/or reverse biological aging, resulting in extended healthspan and lifespan. Interventions delaying aging in animal models are well established; however, most lack validation in humans. The length of human lifespan makes it impractical to perform survival analysis. Instead, aging biomarkers, such as DNA methylation (DNAm) clocks, have been developed to monitor biological age. Herein we report a retrospective analysis of DNA methylation age in 42 individuals taking Rejuvant®, an alpha-ketoglutarate based formulation, for an average period of 7 months. DNAm testing was performed at baseline and by the end of treatment with Rejuvant® supplementation. Remarkably, individuals showed an average decrease in biological aging of 8 years (p-value=6.538x10-12). Furthermore, the supplementation with Rejuvant® is robust to individual differences, as indicated by the fact that a large majority of participants decreased their biological age. Moreover, we found that Rejuvant® is of additional benefit to chronologically and biologically older individuals. While continued testing, particularly in a placebo-controlled design, is required, the nearly 8-year reversal in the biological age of individuals taking Rejuvant® for 4 to 10 months is noteworthy, making the natural product cocktail an intriguing candidate to affect human aging.
科研通智能强力驱动
Strongly Powered by AbleSci AI